Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 6Phase 1 4Phase NA 2Phase 3 2Phase 2/3 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × donafenib × Clear all
NCT04418401 2026-02-17

CISLD-8

Zhejiang University

Phase 1 Completed
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04402723 2022-12-01

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Terminated
8 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04472858 2022-11-29

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1 Unknown
30 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT04059874 2019-08-16

Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

First Affiliated Hospital of Zhejiang University

Phase 1 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡